. 2010 Mar 22;107(14):6418–6423. doi: 10.1073/pnas.1001119107

Table 3.

25(OH)D₃ only modestly suppresses EAE

Treatment	Incidence	Day of onset	Peak severity	CDI
Vehicle	87% (13/15)	13 ± 2	2.7 ± 0.8	25 ± 10
10 μg/kg 25 D₃	88% (15/17)	14 ± 3	2.9 ± 0.9	23 ± 16
500 μg/kg 25 D₃	82% (14/17)	16 ± 4^*	2.7 ± 0.6	19 ± 12
1,000 μg/kg 25 D₃	82% (14/17)	16 ± 3^*	2.6 ± 0.6	17 ± 11^*
2.5 μg/kg 1,25 D₃	35% (6/17)^†	20 ± 3^†	2.3 ± 0.6	4 ± 7^†

Female C57BL/6 mice were treated with either 25(OH)D₃ or 1,25(OH)₂D₃ in the indicated doses delivered in purified diet. All mice were immunized with MOG_35–55 10 days after initiating therapy with the vitamin D metabolites. Mice were monitored daily for 25 days and assessed clinically for signs of EAE. The clinical data demonstrate the mean ± SD from one representative of three individual experiments.

*P < 0.05 compared with the vehicle group.

^†P < 0.05 compared with all other groups.